28220082|t|Synaptic and Neuronal Autoantibody - Associated Psychiatric Syndromes: Controversies and Hypotheses
28220082|a|Autoimmune encephalitis (AE) mediated by antibodies against synaptic and neuronal surface targets frequently presents with a psychiatric syndrome. In these patients, removal of autoantibodies treats the disease and outcomes are closely linked to early intervention. The discovery of these autoantibodies in isolated psychiatric syndromes has raised the possibility that these patients may derive similar benefits from immunotherapy, a potentially transformational approach to the treatment of mental illness. Although open-label case series suggest impressive therapeutic outcomes, the pathological relevance of these autoantibodies outside of canonical presentations is debated. The advent of diagnostic criteria for AE attempts to facilitate its prompt identification but risks prematurely neglecting the potential scientific and clinical significance of isolated syndromes that do not satisfy these criteria. Here, we propose using a syndrome - level taxonomy that has occasional, but not necessary, overlap with AE: synaptic and neuronal autoantibody - associated psychiatric syndromes or " SNAps ". This will prevent confusion with AE and act heuristically to promote active investigation into this rare example of psychopathology defined on a molecular level. We suggest that this concept would have application in other autoantibody - associated syndromes including seizure, cognitive, and movement disorders, in which similar issues arise. We review putative direct and indirect mechanisms and outline experimentally testable hypotheses that would help to determine prospectively in whom autoantibody detection is relevant, and as important, in whom it is not. We summarize a pragmatic approach to autoantibody testing and management in severe mental illness in order to promptly diagnose AE and advocate a research - orientated experimental medicine paradigm for SNAps, where there is greater equipoise. We conclude that SNAps remains a nascent area of clinical neuroscience with great potential and in ongoing need of psychiatry -led basic and clinical research.
28220082	0	8	Synaptic	T030	C0039062
28220082	13	21	Neuronal	T025	C0027882
28220082	22	34	Autoantibody	T116,T129	C0004358
28220082	37	47	Associated	T080	C0332281
28220082	48	69	Psychiatric Syndromes	T048	C0004936
28220082	71	84	Controversies	T054	C0680243
28220082	89	99	Hypotheses	T078	C1512571
28220082	100	123	Autoimmune encephalitis	T047	C0393639
28220082	125	127	AE	T047	C0393639
28220082	141	151	antibodies	T116,T129	C0003241
28220082	160	168	synaptic	T030	C0039062
28220082	173	181	neuronal	T025	C0027882
28220082	182	189	surface	T082	C0205148
28220082	190	197	targets	T169	C1521840
28220082	198	208	frequently	T079	C0332183
28220082	209	217	presents	T033	C0150312
28220082	225	245	psychiatric syndrome	T048	C0004936
28220082	256	264	patients	T101	C0030705
28220082	266	276	removal of	T061	C0015252
28220082	277	291	autoantibodies	T116,T129	C0004358
28220082	292	298	treats	T169	C1522326
28220082	303	310	disease	T047	C0012634
28220082	315	323	outcomes	T080	C0085415
28220082	352	364	intervention	T061	C0184661
28220082	370	379	discovery	T052	C1880355
28220082	389	403	autoantibodies	T116,T129	C0004358
28220082	407	415	isolated	T169	C0205409
28220082	416	437	psychiatric syndromes	T048	C0004936
28220082	442	448	raised	T080	C0442818
28220082	476	484	patients	T101	C0030705
28220082	504	512	benefits	T081	C0814225
28220082	518	531	immunotherapy	T061	C0021083
28220082	535	546	potentially	T080	C3245505
28220082	564	572	approach	T082	C0449445
28220082	580	589	treatment	T169	C0039798
28220082	593	607	mental illness	T048	C0004936
28220082	618	640	open-label case series	T062	C3640652
28220082	660	680	therapeutic outcomes	T080	C0085415
28220082	686	698	pathological	T169	C1521733
28220082	699	708	relevance	T080	C2347946
28220082	718	732	autoantibodies	T116,T129	C0004358
28220082	744	767	canonical presentations	T081	C0870245
28220082	794	813	diagnostic criteria	T170	C0679228
28220082	818	820	AE	T047	C0393639
28220082	821	829	attempts	T051	C1516084
28220082	855	869	identification	T080	C0205396
28220082	874	879	risks	T078	C0035647
28220082	907	916	potential	T080	C3245505
28220082	917	927	scientific	T090	C0036397
28220082	932	953	clinical significance	T033	C2826293
28220082	957	965	isolated	T169	C0205409
28220082	966	975	syndromes	T047	C0039082
28220082	1037	1045	syndrome	T047	C0039082
28220082	1048	1053	level	T080	C0441889
28220082	1054	1062	taxonomy	T090	C0087066
28220082	1072	1082	occasional	T079	C0521114
28220082	1103	1110	overlap	T079	C1948020
28220082	1116	1118	AE	T047	C0393639
28220082	1120	1128	synaptic	T030	C0039062
28220082	1133	1141	neuronal	T025	C0027882
28220082	1142	1154	autoantibody	T116,T129	C0004358
28220082	1157	1167	associated	T080	C0332281
28220082	1168	1189	psychiatric syndromes	T048	C0004936
28220082	1195	1200	SNAps	T048	C0004936
28220082	1214	1221	prevent	T169	C1292733
28220082	1237	1239	AE	T047	C0393639
28220082	1244	1261	act heuristically	T170	C0597916
28220082	1265	1272	promote	T052	C0033414
28220082	1273	1279	active	T169	C0205177
28220082	1280	1293	investigation	T058	C0220825
28220082	1304	1308	rare	T080	C0522498
28220082	1309	1316	example	T077	C1707959
28220082	1320	1335	psychopathology	T091	C0033927
28220082	1336	1343	defined	T170	C1704788
28220082	1349	1364	molecular level	T081	C0596958
28220082	1387	1394	concept	T078	C0178566
28220082	1427	1439	autoantibody	T116,T129	C0004358
28220082	1442	1452	associated	T080	C0332281
28220082	1453	1462	syndromes	T047	C0039082
28220082	1463	1472	including	T169	C0332257
28220082	1473	1480	seizure	T184	C0036572
28220082	1482	1491	cognitive	T169	C1516691
28220082	1497	1515	movement disorders	T047	C0026650
28220082	1526	1533	similar	T080	C2348205
28220082	1534	1540	issues	T033	C0033213
28220082	1551	1557	review	T169	C0699752
28220082	1567	1573	direct	T080	C1947931
28220082	1578	1586	indirect	T080	C0439852
28220082	1587	1597	mechanisms	T169	C0441712
28220082	1610	1624	experimentally	T080	C1517586
28220082	1634	1644	hypotheses	T078	C1512571
28220082	1674	1687	prospectively	T062	C0033522
28220082	1696	1708	autoantibody	T116,T129	C0004358
28220082	1709	1718	detection	T061	C1511790
28220082	1722	1730	relevant	T080	C2347946
28220082	1739	1748	important	T080	C3898777
28220082	1784	1793	pragmatic	T054	C0871858
28220082	1806	1818	autoantibody	T116,T129	C0004358
28220082	1819	1826	testing	T169	C0039593
28220082	1831	1841	management	T058	C0376636
28220082	1845	1851	severe	T080	C0205082
28220082	1852	1866	mental illness	T048	C0004936
28220082	1888	1896	diagnose	T033	C0011900
28220082	1897	1899	AE	T047	C0393639
28220082	1915	1923	research	T062	C0035168
28220082	1926	1936	orientated	T033	C0424013
28220082	1937	1949	experimental	T080	C1517586
28220082	1950	1958	medicine	T121	C0013227
28220082	1959	1967	paradigm	T062	C0681797
28220082	1972	1977	SNAps	T048	C0004936
28220082	1994	2001	greater	T081	C1704243
28220082	2002	2011	equipoise	T109,T121	C0702057
28220082	2030	2035	SNAps	T048	C0004936
28220082	2062	2070	clinical	T080	C0205210
28220082	2071	2083	neuroscience	T091	C0027910
28220082	2095	2104	potential	T080	C3245505
28220082	2112	2119	ongoing	T078	C0549178
28220082	2120	2124	need	T080	C0027552
28220082	2128	2138	psychiatry	T091	C0033873
28220082	2154	2171	clinical research	T062	C0008972